Company profile

Chong Kun Dang Pharmaceutical

Diversified pharma

185750 · KRX · South Korea

Public Market Listing

185750KRX

KRX primary exchange listing

Live quotes, historical charts, and market capitalization for Chong Kun Dang Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
0Approved
1Phase 3 / Filed
6Phase 1–2 / Early
6Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
CKD-701No recent activity
Phase 3
VEGF-ABiologic — subtype unspecified
Age-Related Macular Degeneration
CKD-506No recent activity
Phase 2
HDAC6 (Histone deacetylase 6)
Rheumatoid Arthritis
CKD-703
Phase 2
METSmall molecule
Non-Small Cell Lung Cancer
CKD-385No recent activity
Phase 1
Undisclosed / early pipelineSmall molecule
Hypertension
CKD-706
Phase 1
IL-4R-alphaMonoclonal antibody
Atopic Dermatitis
Lobeglitazone(Duvie)
Phase 1
PPAR-gammaSmall molecule
Type 2 Diabetes
tofacitinib (Chong Kun Dang)No recent activity
Phase 1
JAK1/JAK3
Rheumatoid Arthritis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.